Development of a Modular Ribonucleoprotein Complex as a General Strategy to Deliver RNAi Therapeutics

Area of Science:

• Biotechnology
• Molecular Biology
• Drug Delivery

Background:

• RNAi therapeutics offer potential for treating diseases currently considered undruggable.
• Significant challenges in RNAi therapeutic development are associated with efficient and safe delivery systems.
• Existing delivery methods often face limitations in biocompatibility, modularity, and customization.

Purpose of the Study:

• To develop a novel, biocompatible, and modular platform for delivering small interfering RNA (siRNA) therapeutics.
• To overcome the limitations of current RNAi delivery systems.
• To demonstrate the efficacy of the developed platform in preclinical cancer models.

Main Methods:

• Remodeling the human U4 small nuclear ribonucleoprotein complex (snRNP) to create a protein-siRNA complex (SmiRNP).
• Utilizing siRNA targeting KRAS as a proof of principle for the SmiRNP platform.
• Evaluating the SmiRNP complex's ability to deliver siRNA into cells, protect against nuclease degradation, and achieve target knockdown in vitro and in vivo.

Main Results:

• The SmiRNP complex successfully delivered siRNA into cells, protecting it from degradation.
• Demonstrated significant knockdown of KRAS mRNA and protein levels.
• Observed reduced cancer cell viability and suppressed tumor growth in vivo.

Conclusions:

• The SmiRNP platform provides a biocompatible, modular, and customizable approach for RNAi delivery.
• This strategy effectively overcomes key delivery hurdles for RNAi therapeutics.
• The SmiRNP system holds promise for enabling a wide spectrum of RNAi-based treatments for various diseases.